Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease.

Yuajit C, Muanprasat C, Gallagher AR, Fedeles SV, Kittayaruksakul S, Homvisasevongsa S, Somlo S, Chatsudthipong V.

Biochem Pharmacol. 2014 Apr 1;88(3):412-21. doi: 10.1016/j.bcp.2014.01.038. Epub 2014 Feb 8.

PMID:
24518257
2.

Steviol reduces MDCK Cyst formation and growth by inhibiting CFTR channel activity and promoting proteasome-mediated CFTR degradation.

Yuajit C, Homvisasevongsa S, Chatsudthipong L, Soodvilai S, Muanprasat C, Chatsudthipong V.

PLoS One. 2013;8(3):e58871. doi: 10.1371/journal.pone.0058871. Epub 2013 Mar 11.

3.

Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase.

Pathomthongtaweechai N, Soodvilai S, Chatsudthipong V, Muanprasat C.

Eur J Pharmacol. 2014 Feb 5;724:67-76. doi: 10.1016/j.ejphar.2013.12.013. Epub 2013 Dec 17.

PMID:
24360935
4.

Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.

Cebotaru L, Liu Q, Yanda MK, Boinot C, Outeda P, Huso DL, Watnick T, Guggino WB, Cebotaru V.

Kidney Int. 2016 Jul;90(1):90-9. doi: 10.1016/j.kint.2016.01.026. Epub 2016 Mar 25.

5.

Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.

Takiar V, Nishio S, Seo-Mayer P, King JD Jr, Li H, Zhang L, Karihaloo A, Hallows KR, Somlo S, Caplan MJ.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2462-7. doi: 10.1073/pnas.1011498108. Epub 2011 Jan 24.

6.

Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway.

Xu T, Wang NS, Fu LL, Ye CY, Yu SQ, Mei CL.

Mol Biol Rep. 2012 Jul;39(7):7743-53. doi: 10.1007/s11033-012-1611-2. Epub 2012 Mar 14.

7.

Ouabain Regulates CFTR-Mediated Anion Secretion and Na,K-ATPase Transport in ADPKD Cells.

Jansson K, Venugopal J, Sánchez G, Magenheimer BS, Reif GA, Wallace DP, Calvet JP, Blanco G.

J Membr Biol. 2015 Dec;248(6):1145-57. doi: 10.1007/s00232-015-9832-7. Epub 2015 Aug 20.

8.

The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.

Buchholz B, Klanke B, Schley G, Bollag G, Tsai J, Kroening S, Yoshihara D, Wallace DP, Kraenzlin B, Gretz N, Hirth P, Eckardt KU, Bernhardt WM.

Nephrol Dial Transplant. 2011 Nov;26(11):3458-65. doi: 10.1093/ndt/gfr432. Epub 2011 Jul 29.

PMID:
21804086
9.

Activation of AMP-activated protein kinase by a plant-derived dihydroisosteviol in human intestinal epithelial cell.

Muanprasat C, Sirianant L, Sawasvirojwong S, Homvisasevongsa S, Suksamrarn A, Chatsudthipong V.

Biol Pharm Bull. 2013;36(4):522-8. Epub 2013 Jan 24.

10.

Steviol stabilizes polycystin 1 expression and promotes lysosomal degradation of CFTR and β-catenin proteins in renal epithelial cells.

Yuajit C, Muanprasat C, Homvisasevongsa S, Chatsudthipong V.

Biomed Pharmacother. 2017 Oct;94:820-826. doi: 10.1016/j.biopha.2017.07.165. Epub 2017 Aug 10.

PMID:
28802235
11.

Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth.

Li H, Yang W, Mendes F, Amaral MD, Sheppard DN.

Am J Physiol Renal Physiol. 2012 Oct 15;303(8):F1176-86. doi: 10.1152/ajprenal.00130.2012. Epub 2012 Aug 8.

12.

Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models.

Zhou H, Gao J, Zhou L, Li X, Li W, Li X, Xia Y, Yang B.

Am J Physiol Renal Physiol. 2012 May 15;302(10):F1234-42. doi: 10.1152/ajprenal.00356.2011. Epub 2012 Feb 15.

13.
14.

Endogenous concentrations of ouabain act as a cofactor to stimulate fluid secretion and cyst growth of in vitro ADPKD models via cAMP and EGFR-Src-MEK pathways.

Jansson K, Nguyen AN, Magenheimer BS, Reif GA, Aramadhaka LR, Bello-Reuss E, Wallace DP, Calvet JP, Blanco G.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F982-90. doi: 10.1152/ajprenal.00677.2011. Epub 2012 Aug 1.

15.

Therapeutic potential of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors in polycystic kidney disease.

Li H, Sheppard DN.

BioDrugs. 2009;23(4):203-16. doi: 10.2165/11313570-000000000-00000. Review.

PMID:
19697963
16.

[Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)].

Miranda N, Miranda F, Rinaldi L, Stratigis S, Capasso G.

G Ital Nefrol. 2013 Jan-Feb;30(1). pii: gin/30.1.2. Review. Italian.

PMID:
23832438
17.

Regulation of CFTR Expression and Arginine Vasopressin Activity Are Dependent on Polycystin-1 in Kidney-Derived Cells.

de Lemos Barbosa CM, Souza-Menezes J, Amaral AG, Onuchic LF, Cebotaru L, Guggino WB, Morales MM.

Cell Physiol Biochem. 2016;38(1):28-39. doi: 10.1159/000438606. Epub 2016 Jan 8.

18.

Strategies to inhibit cyst formation in ADPKD.

Calvet JP.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1205-11. doi: 10.2215/CJN.05651207. Epub 2008 Apr 23.

19.

Role of CFTR in autosomal recessive polycystic kidney disease.

Nakanishi K, Sweeney WE Jr, Macrae Dell K, Cotton CU, Avner ED.

J Am Soc Nephrol. 2001 Apr;12(4):719-25.

20.

Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.

Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP.

Am J Physiol Renal Physiol. 2011 Nov;301(5):F1005-13. doi: 10.1152/ajprenal.00243.2011. Epub 2011 Aug 3.

Supplemental Content

Support Center